Figure 2: Graphs illustrating the effects of electroacupuncture on tumor growth ((a)–(f)) using the following six treatment schedules: (a) EA given once per week beginning on PID 7 (EA-1X/7); (b) EA given twice per week beginning on PID 3 (EA-2X/3); (c) EA given twice per week beginning on PID 5 (EA-2X/5); or (d) PID 7 (EA-2X/7); (e) three EA treatments given prior to implantation (EA-Pro); and (f) EA given once on PID 1 (EA-Once/1). EA-1X/7 treatment resulted in increased tumor growth that was more robust in males (M) versus their female (F) and control counterparts ((a); –11/group). EA-2X/3 produced the longest lasting antitumor growth effects of all the EA regimens tested for both male and female animals ((b); –11/group). EA-2X/5 provided late antitumor effects beginning at PID 21 ((c); –11/group). Conversely, EA-2X/7 elicited a marked increase in tumor growth, which began earlier in female animals ((d); –11/group). EA-Pro also elicited a protumor growth response at PID 21 that was only significantly different in males. ((e), –11/group). Neither EA-Once/1 or any of the sham treatment regimens had any effect on tumor growth and were comparable to their Tumor-No EA controls ((f), –11/group, sham not shown). Data shown as mean % response ± SEM, * , ** , *** , and **** as compared to the Tumor-No EA control groups).